The purpose of this study is to investigate the long-term outcomes of conservative management in patients with moyamoya disease and their first-degree relatives, and provide potential pathogenesis of moyamoya disease.
Moyamoya disease (MMD) is a chronic occlusive-stenosis cerebrovascular disease that characterized by the stenosis of internal carotid artery termination and the formation of net-like vessel. It is a multifactorial disease caused by genetic, inflammatory, immunological and other environmental factors. The specific pathogenesis of MMD is still unclear. The treatment modalities of revascularization and conservative management have been used in patients with MMD. However, the long-term outcomes of MMD with conservative management remain unknown. Also, some first-degree relatives who are carriers of genetic variants occasionally manifest with intracranial arterial stenosis. Therefore, it is significant to detect the long-term outcomes of conservative treatment in MMD patients and their first-degree relatives, and thus provide potential pathogenesis of MMD.
Study Type
OBSERVATIONAL
Enrollment
400
Patients and their first-degree relatives will be medically treated with antiplatelets, antiepileptics, antihypertensives and vasodilators depending on the presentation.
Beijing Tiantan Hospital Capital Medical University
Beijing, Beijing Municipality, China
RECRUITINGCerebrovascular events
Time frame: 6 months
Cerebrovascular events
Time frame: 1 year
Cerebrovascular events
Time frame: 2 years
Cerebrovascular events
Time frame: 5 years
Identification of RNF213 variants
Time frame: Baseline
Unfavorable neurological outcome (mRS>2)
Time frame: 6 months, 1 year, 2 years, and 5 years during follow-up
Change in cerebral perfusion status as assessed by CTP
Time frame: Baseline, 6 months, 1 year, 2 years, and 5 years during follow-up
Change in immunological, inflammatory, angiogenesis biomarkers of peripheral blood
Serum, plasma, RNA, immune cells and cytokines
Time frame: Baseline, 1 year, 2 years, and 5 years during follow-up
Change in angiographic features as assessed by CTA
Time frame: Baseline, 6 months, 1 year, 2 years, and 5 years during follow-up
Change in angiographic characteristics as assessed by MRA
Time frame: Baseline, 1 year, 2 years, and 5 years during follow-up
Change in radiological characteristics as assessed by HR-MRI
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Baseline, 1 year, 2 years, and 5 years during follow-up